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OBJECTIVES: Modelling and forecasting the con-
sequences of AIDS on economic growth in Africa.
METHODS: Our model is based on two crucial hypoth-
esis: AIDS has a short-term impact on a ﬂow variable (the
ﬂow of labour available and capable of working at a
moment t in the economy); AIDS has a long-term impact
on stock variables (human capital, i.e. the stock of health
or the stock of education and competence incorporated
in the workers; and physical capital). The ﬁrst effect is
generally taken into account in the existing literature but
the second is missing. Data from Ivory Coast (data given
by UNAIDS and WHO) about macroeconomic variables
and epidemiologic situations are used to calibrate our
model. RESULTS: Integrating these two impacts in a
model of growth with multiple factors of accumulation is
sufﬁcient to reverse the standard impact-evaluations
based on classical tools. We show that, under a realistic
range of epidemiological shocks, an involution trap can
appear, corresponding to a modiﬁcation of the long-term
growth regime of the economy. CONCLUSIONS: When
the long term impact of AIDS is taken into account, the
impact of AIDS on economic growth in Africa is far worse
than predicted by UNAIDS for instance. In Ivory Coast,
the GDP loss is about 15% of the no-AIDS scenario in
2010 (against -8% for the UNAIDS forecast).
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OBJECTIVES: To investigate the potential role of phar-
macoeconomics in decision making and education.
METHODS: A group of 102 people with backgrounds in
health economics/pharmacoeconomics was interviewed.
Interviewees were students (23), medical doctors (28),
pharmacists (36), managers/economists (22) by educa-
tion, working in hospitals, outpatient clinics, pharmacies,
and the pharmaceutical industry. They were asked about:
sources of information that should be used by decision
makers at different levels of a Health care sector, barriers
to practical application of pharmacoeconomic evaluation
results, criteria for inclusion/exclusion of drugs in a hos-
pital formulary, means by which economic evaluation uti-
lization could become more common, needs for education
initiatives. RESULTS: A total of 86% of responders indi-
cated that expert opinion and 66% that articles in
reviewed scientiﬁc journals are the most important source
of information for reimbursement decisions. At manage-
ment level, also expert opinion (77%) and scientiﬁc jour-
nals (65%) played a key role. In relations between
pharmacist / physician and patient, personal opinion is
vital (58%), followed by experts’ opinion (55%) and
information from scientiﬁc press (50%). Limited interest
in pharmacoeconomic analyses focusing only on cost-
containment (77%) followed by lack of Governmental
Agencies’ involvement in introduction of regulations
(61%), difﬁculties in applying long-term view (57%) and
limited access to cost data (lack of national cost database)
(57%) were recognized as main barriers. On inclusion to
hospital formulary, acquisition cost (70%) and efﬁcacy
(96%) were crucial, hospital savings were less important
(50%). Wider use of pharmacoeconomic studies may be
due to more educational initiatives (74%), creation of
professional cost databases (72%) and transparent crite-
ria of evaluation (69%). A total of 86% of responders
declared the need to expand their knowledge. CON-
CLUSIONS: Education, cost databases and regulations
seem to be the most important in the future development
of pharmacoeconomics and health economics in Poland.
Conﬁrmation of these preliminary results requires
broader investigation.
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OBJECTIVES: To identify the main causes of variation in
study results from place to place, to assess whether the
variation differs by type of health economic study, to
assess whether differences among countries are systematic
and whether the differences are important for decision-
making. METHODS: A literature search was conducted
to identify economic evaluations of pharmaceuticals 
conducted in two or more European countries. These
included reports of multicountry studies and separate
reports of single country studies that were sufﬁciently
methodologically comparable. The studies identiﬁed were
then classiﬁed by methodological type and analysed to
assess their level of generalizability and to identify the
main causes of variation. Assessments were also made of
the extent to which differences in study results among
countries were systematic and whether they would lead
to a different decision, assuming a range of values of the
threshold willingness-to-pay for a life-year or quality-
adjusted life-year (QALY). RESULTS: In total 46 
intercountry drug comparisons were identiﬁed, 29 in mul-
ticountry studies and 17 in single country studies that
were considered to be sufﬁciently comparable in terms of
methodology. The type of study (i.e. trial-based or mod-
elling study) had some impact on generalizability, but a
more important factor was the extent of variation across
countries, in effectiveness, resource use or unit costs,
allowed by the researcher’s chosen methodology. Cost-
effectiveness results did differ widely between countries
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and in general such differences were not systematic (e.g.
the result for Germany was not always more favourable
than that for the UK). However, if a cost-effectiveness
threshold (i.e. willingness-to-pay) for a life-year or QALY
of $50,000 were assumed, the implications for decision-
making would be similar across countries. CONCLU-
SIONS: It is concluded that, where the analyst allows
factors to vary, cost-effectiveness results differ by country.
However, the implications of such variation for decision-
making depend critically on the cost-effectiveness thresh-
olds applying in Europe.
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Therapeutic innovations are generating increasing pres-
sure on health care budgets particularly for hospitals.
Health care professionals are confronted with budgetary,
ethical and equity issues when no explicit criteria for
choice have been set by the community. Reviews of cost-
advantage proﬁle for costly innovations are rare. OBJEC-
TIVE: This work seeks to analyse propensity and capacity
of health systems to ﬁnance therapeutic innovations
according to their cost/advantages proﬁle. METHODS: A
literature review was carried out. A series of therapeutic
innovations addressing life-threatening conditions were
identiﬁed between 1988 and 2003. They were selected
according to: whether they were considered as innova-
tions at time of their introduction into the market and
their cost high. Forty-four publications in peer-reviewed
journals were selected. Innovations were classiﬁed
according to severity of the condition and the treatment
impact on vital prognosis and survival. Reported costs
were actualised to 2002 values. Common indicators
across studies were identiﬁed. RESULTS: The cost per
year of life saved (YLS) for breast cancer treated for com-
binations including paclitaxel in Europe varies between
€7800 and €14000; at 5 years, the cost for trastuzumab/
paclitaxel association is €23000 in UK. This is between
€7000 and €14000 for ovarian cancer. Cost per YLS 
for myocardial infarctus treated by alteplase in France 
is €12000. It varies between €45000 and €79000 
for implantable cardiac deﬁbrillators. This cost varies
between €10000 to €12000 in Europe and around
€12000 in France for drotrecogin alfa (activated) (recom-
binant human activated protein C) for treatment of severe
sepsis with multiple organ failure, recently launched in
France. CONCLUSIONS: Pharmaco-economic indicators
such as cost per YLS can assist payors in decision-making
process when confronted with costly innovations in
chronic and acute disease. A further step is to consider
the budget impact, taking into account criteria such as
incidence, prevalence, severity, and mortality.
HEALTH CARE POLICY—Cost Studies
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OBJECTIVES: Financing of hospital services in Germany
is presently transformed to a DRG-based system destined
to derive 100% of the hospital revenue. The aim of this
study is to determine whether the German DRG based
reimbursement provides adequate coverage of actual
costs of intensive care unit (ICU) patients. METHODS:
Retrospective analysis of ICU length of stay (LOS) and
direct cost data extracted from patients’ electronic
records from the surgical ICU of the University Hospital
Göttingen, Germany. Cost calculations performed for
1187 patients with LOS > 24 hours over a 24-month
period (January 1, 2000–Decemeber 31, 2001). ICU reim-
bursement calculations based on the speciﬁc G-DRG
according to the individual diagnosis and the ﬁxed ICU
proportion of the G-DRG reimbursement. Direct variable
cost (consumables) were assessed bottom-up by means of
a patient data management system. Personnel cost were
calculated per day of treatment. Actual total costs were
compared with the hypothetical DRG reimbursement.
RESULTS: Total actual cost for ICU services was €5.58
million (mean per patient: €4697), while the correspond-
ing DRG-based total reimbursement was €2.98 million
(mean per patient: €.513). The cost deﬁcit is statistically
signiﬁcant (P < 0.001). Underfunding of the costs was
evident in most DRG classiﬁcations, some with reim-
bursement deﬁcits of over 80%. These differences showed
a signiﬁcant and negative linear correlation with ICU LOS
(R = -0.593, p < 0.001). CONCLUSIONS: The computed
G-DRG based reimbursement for ICU services differed
signiﬁcantly from the actual costs incurred. These ﬁnd-
ings highlight the importance of a more realistic and fair
DRG-based reimbursement of hospital ICU services in
Germany, particularly with respect to patients with
extended LOS.
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